ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
Garching / Munich, Germany – ITM Isotope Technologies Munich SE, a prominent radiopharmaceutical biotech company, has announced its participation in the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit. The event is set to take place in New York City.
Expert Presentations Planned
Several key members of ITM's leadership team will participate in presentations and discussions, shedding light on important topics related to the company and the industry. Dr. Andrew Cavey, CEO of ITM, is expected to deliver a comprehensive corporate presentation. This will highlight ITM’s pipeline of targeted radiopharmaceuticals, covering recent updates and significant upcoming milestones that could lead to advancements in treatment.
Panel Discussions Featuring ITM Leaders
Mr. Roger Estafanos, who serves as the Executive Vice President and Global Head of Radiopharmaceuticals, will join an expert panel discussion titled “Challenging Market Leaders Pluvicto and Lutathera.” This panel aims to explore the current landscape and challenges faced by radiopharmaceutical therapies, scheduled for the morning session at 8:40 am ET.
In addition to this, Dr. Mark Harfensteller, the Chief Operating Officer, will participate in another influential panel focused on the topic of “Isotope Supply.” This discussion, taking place at 10:50 am ET, will cover vital aspects of manufacturing and supply in the radiopharmaceutical sector, leveraging ITM’s extensive experience as both a radioisotope producer and developer of therapeutics.
Contact Information for Inquiries
For additional insights and inquiries, representatives can be contacted through the following channels:
Investor Relations
Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com
ITM Contact
Corporate Communications
Kathleen Noonan / Julia Westermeir
Phone: +49 89 329 8986 1500
Email: communications@itm-radiopharma.com
About ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE is at the forefront of the radiopharmaceutical industry, focusing on developing innovative therapies and diagnostics aimed at hard-to-treat tumors. The company is dedicated to meeting the needs of cancer patients and healthcare professionals by ensuring excellence in the development, production, and global supply of medical radioisotopes.
With an emphasis on enhanced patient benefits, ITM is advancing a robust precision oncology pipeline that includes several Phase 3 studies. These studies integrate the company’s high-quality radioisotopes with diverse targeting molecules. ITM combines its two decades of pioneering expertise in radiopharmaceuticals with a strong industry presence and established global networks to offer patients effective targeted treatments that can significantly improve clinical outcomes and overall quality of life.
Frequently Asked Questions
What is the purpose of the Oppenheimer Summit?
The Oppenheimer Summit aims to discuss advancements and challenges in targeted radiopharmaceutical therapies within oncology.
Who from ITM will be presenting at the summit?
Dr. Andrew Cavey, Mr. Roger Estafanos, and Dr. Mark Harfensteller will be representing ITM at the summit.
What topics will ITM discuss at the summit?
ITM will cover its pipeline related to targeted radiopharmaceuticals, panel discussions on market challenges, and isotope supply issues.
How can I contact ITM for further inquiries?
You can reach out to ITM's investor relations or corporate communications contacts provided in the article.
What is ITM focused on in terms of patient care?
ITM is committed to developing new radiopharmaceutical therapeutics and diagnostics to improve treatment outcomes for cancer patients.
